Daniel Pilsgaard Henriksen

Gabapentin and pregabalin have been associated with an increased risk of fragility fractures. Due to differences in pharmacokinetics, we aimed to assess the fracture‐risk difference between the two medicines. We performed a Danish nationwide new user, high‐dimensional propensity score‐matched cohort study to assess the 90‐day risk of fragility fractures among adults, from January 1996 to December 2018. We applied a high‐dimensional propensity score to match new users of gabapentin with new users of pregabalin in a 1:1 intention‐to‐treat approach. Hazard ratios (HRs), incidence rates (IRs) and incidence rate difference (IRD) were obtained. We identified 388 236 eligible patients of which 294 223 and 98 869 initiated gabapentin and pregabalin, respectively. We included 48 272 matched pairs for further analysis. The mean age was 56 (IQR 44–69) years, and the average follow‐up was approximately 11 500 person‐years (PY). The IRs of fragility fractures were 23.7 (95%CI 21.0–26.7) and 23.2 (95%CI 20.5–26.2) per 1000 PY for gabapentin and pregabalin‐exposed patients, respectively. This yielded an HR of 1.02 (95%CI 0.86–1.21) when using gabapentin as the intervention drug and pregabalin as the reference drug. The IRD was estimated to 0.5 PY (95%CI −3.5–4.5). In conclusion, short‐term risk of fragility fractures among gabapentin initiators was not different compared to those initiating pregabalin.